Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

This publication has 17 references indexed in Scilit:

• A Recombinant Blood‐Stage Malaria Vaccine ReducesPlasmodium falciparumDensity and Exerts Selective Pressure on Parasite Populations in a Phase 1–2b Trial in Papua New Guinea
  The Journal of Infectious Diseases, 2002
• Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
  The Lancet, 2001
• A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers
  Vaccine, 2001
• Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea
  Vaccine, 2000
• Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers
  Vaccine, 2000
• Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant
  Vaccine, 1999
• Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area
  Parasite Immunology, 1997
• Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720
  Vaccine, 1997
• Assessment of the Role of Naturally Acquired Antibody Levels to Plasmodium falciparum Merozoite Surface Protein-1 in Protecting Papua New Guinean Children from Malaria Morbidity
  The American Journal of Tropical Medicine and Hygiene, 1996
• Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria
  Parasite Immunology, 1995